Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.
式(I)的化合物或其药学上可接受的盐是GPCR(GPR119)激动剂,可用于治疗糖尿病和肥胖症。
HETEROCYCLIC GPCR AGONISTS
申请人:PROSIDION LTD
公开号:EP2321305A1
公开(公告)日:2011-05-18
[EN] 3-SUBSTITUTED 5-(PYRROLIDINE-1-CARBONYL) PYRROLIDINE AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] 5-(PYRROLIDINE-1-CARBONYL) PYRROLIDINE 3-SUBSTITUÉE ET SES DÉRIVÉS À USAGE DANS LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
申请人:PROSIDION LTD
公开号:WO2011128394A1
公开(公告)日:2011-10-20
The present invention is directed to therapeutic compounds of formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
[EN] HETEROCYCLIC GPCR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS COUPLÉS AUX PROTÉINES G (GPCR) HÉTÉROCYCLIQUES
申请人:PROSIDION LTD
公开号:WO2010004348A1
公开(公告)日:2010-01-14
Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.